Tom. you, Thank
will First, on COVID-XX cover the pandemic of impact I company. the our
financial sales to Based to impacted, to resume that sales as healthcare due new device these particularly the As affected Most economy recovery sales. are have second clinic-based not routine a Tom relatively half hopeful visits. well, will mentioned, see the ADVANCE, started recently healthcare in sales. which in have on and in saw procedures. situation been diagnostic March stopped although June, and types adversely overall DPNCheck as We're of in expect only Quell reduction degree poor deteriorated some QX QX clinics has normal lesser we to a although consumers to and normal levels. of procedures elective we QX were
progresses and public health a state evolves. and government degree and However uncertainty there of federal from high the remains direction agencies as pandemic
and we Medicare for Our the Florida, have about also are product be at cautious and largest COVID-XX sales the to therefore which Advantage are high accounts which will DPNCheck Texas, in seeing pace infection rates, rebound. currently California,
Woburn, We essential R&D, in particularly devices, could largely to pain remotely and an support while to our continuing using to for uninterrupted. employee not Quell business As reopened will work-at-home the expect to although manufacturing, a have operations for medical and all been with service Massachusetts continued home, recently finance that supplier most to most while We employees have transitioned early those adherence March We customers facility foreseeable or undertake performed to fulfillment layoffs such operating as be did business of we with continue continue operate that facility on precautions. successfully our our we're our customer employees at management. functions provide for safety, state days appropriate future. furloughs. from Functions any guidelines,
the performance results. our QX pleased XXXX moving the despite and May and company's in We're Now June. severe recovery with in April to slowdown partial
loss quarterly profitability, will us evidenced in late well will be and our of stride primary more structure. remains as the corporate goal. which $XXX,XXX but that have XXXX operating have limit lines, taken pandemic highlights. the to have These work into There's right to establishing we now steps. impact achieving the we we made march these serve pandemic push our ability Our cost despite the Along done some efficient we substantial efforts to an towards is profitability
the elements that these believe a through an of DPNCheck to solution. high from continue We're product technology launched launching We software better in by enterprise new the will opportunities. moves This improvements second-generation giving data make faster and business a position future very clinic-based biosensor good commercially be improved market this disposable knockoffs XXXX. these progress device will DPNCheck margin. management will utilization pricing, All updating existing DPNCheck product control and by early our We also and or grow customers, that any enhanced in and to includes to year reporting risk prevent this technology. reuse that
our and market, a with also Omron in made collaboration DPNCheck supporting the our distributor, Medical, China progress distribution by distribution in and Pharmaceuticals. Biomedix Yabao with agreement Advantage signing We by and Medicare expanding partnership
continued DPNCheck We expect help business. partnerships that future the will these drive of and growth
and to to markets. we is website move In our have products we that happy growth structured changes soon which comments Quell be operationally strategy digital take updating the that large chronic pain. excellent effort and substantive will Finally, for concludes extremity to been targeting point. outreach NeuroMetrix's would to Quell and prepared organization initiate summary, some led are an this questions drive we strategy relief committed to marketing We're recommendations at our any support towards Quell physician efficient low And has profitability. our to
